Aptevo Therapeutics INC DEF 14A proxy statements

Aptevo Therapeutics Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for August 21, 2026, to elect directors, ratify auditors, and approve an updated stock incentive plan.

Aptevo Therapeutics Inc. calls a special meeting to approve an amendment to its Certificate of Incorporation and a potential $60 million equity issuance under a Standby Equity Purchase Agreement.

Aptevo Therapeutics Inc. is seeking stockholder approval for a series of critical proposals at its upcoming 2025 Annual Meeting, including a reverse stock split to maintain Nasdaq listing, significant equity issuances for capital, and a new stock incentive plan, all aimed at bolstering its financial position and operational flexibility.

Aptevo Therapeutics is holding a special meeting to seek stockholder approval for a stock issuance and a reverse stock split to maintain its Nasdaq listing and secure funding.

Aptevo Therapeutics is holding a special meeting to seek stockholder approval for a stock issuance, warrant amendments, a reverse stock split, and adjournment authorization.

Aptevo Therapeutics is holding a special meeting of stockholders to vote on proposals including amending the company's certificate of incorporation and approving the issuance of common stock and warrants.

Aptevo Therapeutics Inc. will hold its annual stockholder meeting on June 7, 2024, to vote on the election of directors, ratification of the company's accounting firm, approval of the stock incentive plan, and executive compensation.

Aptevo Therapeutics is holding its annual stockholder meeting on June 7, 2024, to vote on key proposals including the election of directors, ratification of the auditor, and approval of an amended stock incentive plan.